High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy clinical trials

Explore recruiting high intermediate risk hormone receptor hr positive human epidermal growth factor receptor 2 her2 negative breast cancer patients with indication of neoadjuvant therapy clinical trials.

Also recruiting in Europe

High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients “CARABELA Study”

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy trials by city

High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Toronto High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Vancouver High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Montreal High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Calgary High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Edmonton High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Ottawa High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Winnipeg High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Quebec City High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Hamilton High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Kitchener High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in London High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Halifax High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in New York High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Los Angeles High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Chicago High Intermediate Risk Hormone Receptor Hr Positive Human Epidermal Growth Factor Receptor 2 Her2 Negative Breast Cancer Patients With Indication Of Neoadjuvant Therapy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease